INTRODUCTION
The role of medical imaging in the preclinical, pharmaceutical environment has entered a growth phase in the drug discovery setting due to at least three main factors: (i) improved technology, specific to the imaging of small animals; (ii) the high-visibility impact of imaging on the practice of human medicine; and (iii) operational advantages leading to a competitive advantage over other drug discovery organizations (1, 2) . However, it is important to note that as much as one could make the case to employ imaging, it must also be emphasized that an organizational investment-both monetary and operationally-must be made for the proper implementation and integration of imaging into a company's drug development work flow (1, 2) . Still the question remains: What is the role of imaging, both molecular and anatomical, in improving the current drug discovery process? This article examines this question in light of the experiences of the authors in establishing an Imaging Sciences Group at Millennium Pharmaceuticals (Cambridge, MA, USA), as well as personal communications with colleagues in the field. First, we will briefly review why imaging could impact pharmaceutical drug development-a process wrought with potential failures-and then highlight specific examples of the approaches that we have taken.
PHARMACEUTICAL DRUG DEVELOPMENT PROCESS
It is well understood that the pharmaceutical drug development is an expensive and risk-intensive process. In 2003, DiMasi and colleagues (3) estimated that the capitalized preclinical cost for the development of a new drug is approximately $335 million, 42% of the $802 million total cost. Compared with a similar analysis performed in 1991 by the same author, the preclinical costs have grown 57% in that 12-year period (4) . Unfortunately for the pharmaceutical industry, the total cost of drug development has increased by 152% during that same time period (from $318 million); however, the approval rate and research and development time have not changed-on average the development of a new drug takes 12 years. One contributing factor is that the attrition rates of promising compounds remains extremely high (5, 6) . More specifically, of all molecules identified in discovery research only 5% advance into clinical trials; and of that 5%, only 20% will complete the approval process for marketed use in humans. Clearly, improving the attrition rate would significantly impact the development and, ultimately, the market cost of drugs.
In general, preclinical scientists must identify, prioritize, and validate cellular and genetic targets of relevance for an unmet clinical need. Thereafter, a variety of chemical designs and optimizations are required to arrive at compounds that are considered "leads." Lead compounds are then subjected to extensive in vitro and in vivo investigation that may span in excess of 6 years. It is only following successful preclinical testing that initial regulatory approval can be sought, and subsequently, clinical trials may begin. Huge financial commitments, as previously stated, are necessary to execute clinical trials. It is imperative, therefore, that compounds are interrogated carefully and that confidence is gained regarding the potential clinical success of a drug candidate.
Although there are imaging approaches that could be used to assess validity of drug targets or chemical safety and toxicity, imaging has more commonly been applied to address the transition between proof-of-concept (PoC) testing in animal models to PoC demonstration in man, which is generally the goal in the phase II clinical trial. In other words, imaging methods can be utilized in the preclinical setting that can also be translated to the clinic to help assess the efficacy of a drug in trials. There still remains a discussion regarding the predictability of animal models of disease with human disease, but that is beyond the scope of this correspondence and in some regard a moot point, because thorough animal testing is a requirement of federal regulatory agencies. Hence, despite the incongruity with the human disease phenotypes, disease modeling in animals is an important and critical necessity for the development of new drugs. It is in this arena that medical imaging is being applied extensively to develop novel, validated, and translatable surrogate markers of efficacy of development drugs. Further, it is worth noting that regulatory agencies have acknowledged the potential use of imaging in clinical trials and preclinical research (7, 8) .
There are at least two approaches to utilizing imaging in a drug discovery setting. One is to directly test the efficacy of chemical compounds on the development of disease in animal models. Another approach is to utilize the animal models to establish some understanding of the imaging biomarkers that could then be used in the clinic. The former-direct efficacy testing-could provide the confidence discussed previously and, further, add valuable data to the package submitted to regulatory agencies. The power of an image of treatment-induced inhibition of tumor growth, for example, should not be underestimated. The latter motivation-the development and characterization of biomarkers-is a less defined role of medical imaging, but it captures the notion that imaging methods can be tested robustly in animals and used to predict the biomarker activity in humans. For example, positron emission tomography (PET) imaging methods can be used to track glucose utilization in tissues. This method involves the injection of a radiotracer analog of glucose, 18 F-labeled 2-fluoro-deoxy-D-glucose ( 18 FDG), the decay of which is imaged via PET. The uptake of the 18 FDG radiotracer is directly correlated to the metabolic activity (i.e., glucose utilization) of the tissue; thus 18 FDG PET is an imaging marker of functional metabolism. This method is used both in man and animals. Taking into account the differences in biology between the species, preclinical characterization of the 18 FDG PET signal in animal cancer models could be used to estimate the signal response in human cancers. These studies are most useful for determining the time course of the PET signal and could help determine optimum imaging time points in man, thereby limiting the number of scans and radiation exposure to a patient and optimizing the value of each scan.
Ultimately, preclinical imaging, which can be further subdivided into anatomical and functional modes, has an ever increasing role in pharmaceutical drug development. Improving the preclinical assessment of compound efficacy will aid in the advancement of better compounds-those with a better chance of success in human trials. Thus, in the drug development process, medical imaging is being applied extensively to (i) develop and validate animal models of disease (include transgenic animals); (ii) evaluate the efficacy of investigational drugs in those animal disease models using methods that are similar to clinical imaging methods; and (iii) study the complex behavior of imaging biomarkers in a high-throughput and stringent environment. The generation of imaging biomarkers translatable to human studies could facilitate and enhance clinical application development and, possibly, be of great utility for assessing the efficacy of compounds for patients undergoing treatment.
MEDICAL IMAGING TECHNOLOGIES
Thus far, the term medical imaging has been used in a very general sense. Clinically, medical imaging refers to a variety of noninvasive scanning modalities used to diagnose trauma and disease. The preclinical research world, in recent years, has been given imaging scanners designed specifically for use in small animals, but these scanners are identical to those scanners used in clinical medicine in their fundamental physics. Some of these modalities, such as magnetic resonance imaging (MRI), have been available in small animal designs for many years. MRI, in particular, has already been used extensively for drug development (9, 10) . Other modes, such as PET, were until recently only available for humans and, as such, not well suited for small animal research. Now, there are "micro" or miniaturized PET and computed tomography (CT) scanners dedicated for mouse and rat imaging, the animals that are utilized in the bulk of preclinical research. In general, the scanners designed for use with small animals are appreciably smaller, to accommodate the much smaller "patient" (11) . Further, dedicated animal instruments scan with much higher resolution than the clinical instrument. There is an increasing number of reports of novel applications of small animal imaging scanners for the characterization of disease and pharmaceutical intervention, especially in the field of molecular imaging (12) (13) (14) (15) (16) . Our laboratory, for example, has demonstrated the coordination of molecular and anatomical imaging methods that highlight the antitumor activity of MLN2704 on a murine model of osteoblastic prostate cancer metastasis (17) (18) (19) .
MLN2704, which is currently in phase 1/2 development, is a novel therapeutic designed to deliver the maytansanoid chemotherapeutic agent DM1 directly to prostate cancer cells through the targeting of MLN591, a monoclonal antibody vehicle that binds specifically to the prostate-specific membrane antigen (PSMA). The animal model is based on the 22Rv1 prostate cancer cell line, an androgenindependent derivative of the CWR22 prostate cancer xenograft that was engineered to express firefly luciferase and implanted directly into the proximal bone cavity of the tibia. In these studies, optical (bioluminescence) imaging was used to determine the relative number of active cancer cells via the photon flux of the tumor; CT was used to characterize the bone effects, which included both osteolytic and osteoblastic phases; and MRI was used to visualize the tumor and its invasion into surrounding tissues. In more recent work, yet to be published, we have also characterized the 18 FDG PET signal of the CWR22 tumor cell line in the intraosseous model. Table 1 summarizes the most common modalities available for animal imaging in the pharmaceutical domain. All of these techniques are commonly used in the clinical setting on humans, with the exception being optical imaging; although in the preclinical environment, optical imaging-specifically fluorescence or bioluminescence-is of immense value. The table lists the general method of image contrast (a physics discussion is beyond the scope of this paper) as well as the typical resolution limitations of each scanner. In most cases, the higher resolution scanners (MRI, CT, ultrasound) are superior anatomical modalities. These same scanners, however, have low sensitivity and generally are not as good for functional information. PET, single photon emission computed tomography (SPECT), and optical imaging technologies are highly sensitive and can be used to generate highly informative images directly targeted at functional read-outs such as glucose utilization and protein/gene modulation.
EXAMPLES IN ONCOLOGY RESEARCH
The utility of imaging in preclinical cancer research stems from the fact that clinical oncology is, arguably, the area of medicine that has been most affected by human imaging technology. Imaging has had such a great impact in oncology due to the fact that cancer usually occurs as a disseminated disease with multiple lesions Measuring the extent of disease and the response to treatment was, therefore, quite difficult before the advent of imaging technology made possible the noninvasive visualization of these occult lesions in situ. In that regard, human medicine has embraced imaging technologies for the purposes of assessing otherwise hidden disease. To date, preclinical medical imaging has already made a significant impact in research and the drug discovery process. The use of MRI for the study of cancer is well established. For reference, Table 2 gives a short list of some of the cancer drugs for which MRI research results have been published. This is likely only a subset of the data available, since many pharmaceutical studies are not slated for publication for reasons of confidentiality, thus the true impact of imaging research across the pharmaceutical industry is likely understated by Table 2 . However, anecdotal evidence suggests that not only MRI, but also CT, PET, SPECT, ultrasound, and optical imaging are making a great impact to the research conducted at the world's leading institutions.
Discovery research, without sophisticated and dedicated animal scanners, was forced to deal with the problem of following hidden cancers growing within small animals. This was accomplished by developing a standard animal model in which the cancer has been moved out of the organs and to a more easily observed location: the subcutaneous flank, where the growth of the tumor could be directly measured by calipers. More specifically, the standard oncology research model is the subcutaneous injection of human cancer cell lines into the flank of immunocompromised mice.
In general, these preclinical models of cancer are considered to poorly recapitulate human cancer. First, human cancer cell lines derived for injection into small animals may not present with the same phenotype as the cancer cells that they represent in actual human disease. Second, the location of growth in the standard flank xenograft model does that match the clinical case. In humans, cancer is often a disseminated disease with lesions occurring at unknown sites within the body. In fact, the major causes of pain and death from both breast and prostate cancer result from metastases to bone (20) (21) (22) . To achieve convenience, the flank xenograft model has (i) sacrificed the host's immune function through use of immunocompromised animals-despite immune interaction being of profound importance in cancer; (ii) taken the tumor out of its proper stromal microenvironment-stromal interactions being of enormous importance in most cancers; (iii) precluded the possibility of morbidity associated with organ tissue displacement-this being the major morbidity in clinic; and (iv) eliminated distant metastases altogether-despite the fact that the primary tumor does not typically lead to death in people, who often die of complications due to metastatic lesions (23) . For lack of the means to follow cancer's natural environment, cellular interactions, relevant morbidities, and actual source of mortality, cancer research has settled on a compromised model of disease that offers an easily measured tumor. However, anecdotal evidence suggests that more drug discovery organizations are using imaging tools to supplement their research. The benefit that small animal imaging most clearly offers cancer researchers is the chance to use models that more accurately recapitulate human disease, not the chance to image the expedient model that we have inherited. Companies making an investment in imaging for cancer research must be prepared to make a concomitant investment in advanced animal models.
Despite the arguments against studying cancers with flank xenograft models, it should be born in mind that it is not proven that such advanced cancer models (orthotopic grafts or transgenic models) are superior vehicles for testing of preclinical drug compounds. This is an area of ongoing research and development that must be pursued in parallel with imaging, the facilitating technology for such advanced models research. Although the general opinion in the imaging field is that more accurate disease models can provide at minimum more confidence that a compound is efficacious.
Imaging has become increasingly important at Millennium, and herein we provide some examples of the work that we have conducted. The first example is of a murine model of lung cancer, whereby the tumor cells (in this case, H1299) were injected into the pleural space via an intercostal injection just inferior to the caudal tip of the scapula. Over a period of 2 months, these mice were monitored by MRI to evaluate the growth characteristics of the tumors. Figure 1 shows a magnetic resonance image of two animals, both without external symptoms of cancer upon visual inspection, 44 days post-implantation. In this example, to improve imaging throughput, the animals were scanned together in a 64-mm quadrature volume coil. The scan was acquired on free breathing animals (i.e., no respiratory gating performed) using a proton-density contrast and a fast-spin echo imaging scheme. To aid the reader, the tumors have been outlined in red. In one case, the imaging revealed a substantial tumor with portions in both the lungs and surrounding tissues (animal on the left of Figure 1 ), and following imaging that tumor outgrowth was palpable under the animal's arm. The animal on the right of Figure 1 , had an elongated tumor that appeared adhered to the outer wall of the lung. This particular scan took only 8 min to acquire, allowing for approximately 8-10 animals to be scanned per hour, showing the feasibility of large-scale, pharmaceutically relevant studies. In the studies of the H1299 orthotopic tumors, we found a variety of tumor sizes and growth kinetics, and in all cases, MRI was able to detect tumors far in advance of "clinical" symptoms associated with the cancer that would alter the mouse's appearance (i.e., lethargy, impaired or labored breathing, loss of appetite, cachexia, etc.). The previous example highlights the value of noninvasive imaging for the detection of otherwise occult tumors in situ. Those experiments demonstrate the anatomical aspect of imaging. However, as mentioned, there is a great role for molecular and functional imaging techniques as well. One such example is of a multiple myeloma cell line engineered to express firefly luciferase, which is becoming a widely used technique in cancer research (14) (15) (16) 24) . Briefly, the active domain of the luciferase is inserted into the genome of the cultured cancer cells, which are then tested for luciferase activity and tumorigenesis. In the presence of the substrate luciferin, the luciferase protein catalyzes an oxidation reaction and releases light centered approximately at 550 nm, which is subsequently detected using a cooled charge-coupled device (CCD) camera. Bioluminescence imaging, as it is known, allows researchers to follow cell populations with incredible sensitivity. Using these engineered cells, we created a disseminated model of multiple myeloma. That is, instead of injecting cells into a particular location (e.g., the animal flank), the cells are injected into the blood (via cardiac or vein injection) and allowed to seed randomly in the body. Using bioluminescence imaging, researchers are able to track the cells immediately after injection and into the sites of eventual disease. Figure 2A shows an example of a mouse from the disseminated multiple myeloma study. The pseudocolor overlaid on the image of the animal shows the location and intensity of the emitted light from the animal. In this case, 30 days post-implantation, tumor cells had seeded in the head, left knee, and sacral spine/hip. Further, of particular interest in clinical multiple myeloma is the assessment of bone involvement, which was previously mentioned as a major cause of pain and morbidity in cancer patients. To assess the skeletal structure of the mouse, we utilized microCT imaging, which above all other modes provides the highest contrast for bone imaging. The CT images provided include: (i) a sagittal section through the animal head highlighting the lesion effects on the skull ( Figure 2B) ; (ii) a three-dimensional (3-D) rendered image of the upper torso and head of the animal showing the shoulder and head bone changes ( Figure 2C) ; and (iii) a 3-D rendered image of the animal leg, demonstrating the osteolytic lesion in the distal femur ( Figure 2D) .
Although, orthotopic tumor work speaks to the real strength of medical imaging experiments, there will continue to be a great deal of work remaining in flank xenografts. In that regard, there is still valuable information, beyond just tumor volume, that can be ascertained using medical imaging, and an example is provided. A blood-based CT contrast agent, Fenestra VC (Alerion Biomedical, San Diego, CA, USA), was administered to the animal intravenously (400 µL via lateral tail vein). Fenestra is comprised of iodinated lipids in an oil-in-water lipid emulsion with a vascular residence time of several hours, allowing for detailed images of the vasculature to be acquired via CT. Figure 3 shows a 3-D rendered CT image, viewed from the left side of an animal with a subcutaneous U87 tumor. A large vessel (approximately 1 mm diameter) appears near the heart of the animal and represents the hijacked blood supply that the tumor utilized for growth and survival. Other vessels, branching from the main tumor vessel, can be seen in the periphery of the tumor, while smaller vessels can be seen plunging into the central region of the tumor. In this example, only vessels larger than 300 µm in diameter could be visualized; although it is not known if more contrast agent, more contrast distribution time (this image was acquired in the first hour post-injection), or alternative imaging parameters may improve the sensitivity to smaller vessels.
CHALLENGES
It is important to note at the start, that imaging technology is not like the high-throughput screening technologies that the industry has so successfully adopted in the last 20 years, which had the advantage of being very much like the previous screening approach, only faster. Imaging is altogether a different approach to in vivo monitoring of disease and drug treatment. As such, its implementation requires a multidisciplinary group of scientists to evaluate and acquire the correct scanners, determine the appropriate projects to study, and properly evaluate the imaging data and report the results. In some cases, the ease of use of some instruments can give the false impression that the interpretation of the images is equally trivial, which is most often not true. In the clinical setting, this issue is illustrated by the fact that there are many highly trained radiologists for each scanner in use whose responsibility it is to read the films (or digital images in modern facilities) and generate the report for the referring physician. Preclinical imaging endeavors require ongoing A large vessel that feeds the tumor (approximately 1 mm diameter) appears near the heart of the animal. Other vessels, branching from the main tumor vessel, can be seen in the periphery of the tumor, while smaller vessels can be seen plunging into the central region of the tumor. In this example, only vessels larger than 300 µm in diameter could be visualized.
and active collaborations across various scientific disciplines, since acquisition to interpretation is a complex exercise. Imaging physicists alone are not properly trained to understand the complexities of pathologies and the presentation of disease in live animals. In contrast, pharmacologists alone will not have the proper physics and instrumentation background to fully leverage the scanners and, further, are not trained in the image analysis techniques required. In fact, along with scanning animals and acquiring images, a significant amount of time is spent interrogating and analyzing the images. In that regard, the team is challenged to correctly identify and quantify lesions. The challenge of quantifying the disease is compounded by the fact that with new disease models comes unknown imaging features, which in many cases may have no publication history from which to draw some experience. The imaging scientist is required to spend a significant amount of time running preliminary pilot experiments to optimize image contrast as well as imaging time (required for adequate throughput) and creating or modifying data analysis methods and software to generate robust and trustworthy postprocessing data.
The amount of data generated in a preclinical imaging study can be significant, and often semi-automated steps are vital for the timely completion of the data analysis. For example, we study the effects of disease on bone, including the disseminated multiple myeloma model previously discussed and small animal models of rheumatoid arthritis, a chronic disease characterized by inflammation and bone destruction. To facilitate the analysis of the microCT generated, we have developed several novel algorithms, such as one that automatically segments individual bones from a 3-D data set. The segmentation procedure is often a precursor to other analysis methods, which may measure such features as bone surface roughness, volume, density, etc. The time and effort required by a researcher to perform the tedious job of object segmentation is not trivial. Automated techniques, such as bone segmentation, can free researchers from mundane tasks, provided that the imaging scientists are capable of developing the computer algorithms to perform those tasks with equal precision to the human. Figure 4 demonstrates two series of images created during the stages of bone segmentation in our algorithm (unpublished). Briefly, the algorithm performs a series of filters, morphological operations, and signal thresholds while comparing the output with the input image. The result is a mask of the original data that can be used to create individual data sets for each object (bone) of interest. The top series in Figure 4 is the segmentation performed on a microCT image of a rat ankle, and the bottom series is the segmentation of a microCT of a mouse knee. In both series, panel a is the original image (a single slice from a large 3-D data set). Panels b-e represent various filters and morphological operations that are used to manipulate the mask image, improving that match to the original image. Panel f is the final mask, the output of the segmentation algorithm. Panel g is included to show the overlay of the segmented mask and the original image. The mask is pseudocolored to identify the individual bones. Note the good spatial correspondence between the original shape and boundaries and those found in the segmentation algorithm. Lastly, a zoom in of the junction (panel h) between two objects is shown demonstrating that even objects in close proximity can be segmented successfully. Given the large scope of preclinical pharmaceutical studies, the analysis of hundreds of data sets is not uncommon, and automated algorithms such as bone segmentation can greatly impact the throughput of data and results. . Two examples of an automatic bone segmentation program that can be used to significantly enhance data analysis. The algorithm was created specifically for the segmentation of bones from microCT images. The top series of images shows the algorithm applied to a three-dimensional (3-D) microCT data set of a rat ankle, and the bottom series is the data acquired from a mouse knee. In both examples, panel a is a single slice of the original data set. Panels b-e represent various filters and morphological operations that are used to manipulate the mask image, improving that match to the original image. Panel f is the final output of the segmentation algorithm, and panel g is a pseudocolored overlay of the segmented mask and the original image. Lastly, a zoom in of the junction (panel h) between two objects is shown demonstrating that even objects in close proximity can be segmented successfully. Note the good spatial correspondence between the original shape and boundaries and those found in the segmentation algorithm. CT, computerized tomography.
CONCLUSION
There is certainly a growing role for medical imaging in preclinical drug discovery; and in that regard, it must be emphasized that the critical backdrop of all this work is the pharmaceutical company's development of a drug that will hopefully improve the lives of human patients. To that end, it is the goal of imaging scientists to proceed with purpose and caution to develop and implement reliable preclinical imaging assays that will add significant value for drug development efforts.
